Qiagen Stock Price, News & Analysis

QIAGEN has entered an exclusive partnership with Helix to enhance companion diagnostics for hereditary diseases. The collaboration will utilize Helix's laboratory platform and QIAGEN's regulatory expertise to accelerate patient recruitment and real-world evidence generation. This partnership aims to provide innovative diagnostic solutions for neuro-degenerative, cardiovascular, and autoimmune diseases, benefiting hundreds of millions globally. QIAGEN will exclusively market Helix's companion diagnostic services in the U.S., leveraging their extensive network and experience in precision medicine.

Helix and QIAGEN have announced a global strategic partnership to co-develop companion diagnostics for hereditary diseases. This collaboration will utilize the Helix Laboratory Platform alongside QIAGEN's diagnostic technologies. The partnership aims to tackle significant health issues, such as neuro-degenerative and cardiovascular diseases. Helix's platform is the first FDA-approved Class II diagnostic system, enhancing patient recruitment for clinical trials. The two companies plan to reveal further details at the upcoming JPMorgan Health Care Conference in San Francisco.

QIAGEN has received FDA approval for its therascreen KRAS RGQ PCR kit as a companion diagnostic for KRAZATI (adagrasib), targeting non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. This marks the 4th approval of the kit, expanding treatment options for an underserved population with high unmet needs. The kit is designed for fast, cost-effective testing, allowing for timely and informed treatment decisions. QIAGEN's advancements reflect strong collaboration with Mirati Therapeutics and underscore their leadership in RAS companion diagnostics.

QIAGEN N.V. (NYSE: QGEN) reported Q3 2022 net sales of $500 million, down 7% year-over-year, but above expectations of $510 million at constant exchange rates (CER). Adjusted diluted EPS was $0.53, exceeding a forecast of $0.48 CER. Notably, the non-COVID product portfolio saw 18% CER growth to $417 million. The company raised its full-year sales outlook to $2.25 billion CER and adjusted diluted EPS to $2.40 CER, reflecting strong cash flow and robust demand for its solutions.

QIAGEN N.V. (NYSE: QGEN) announced it will release its third-quarter 2022 results on November 7 at 22:05 Frankfurt time. A conference call for discussion will occur the following day, November 8, at 15:00 Frankfurt time. Participants can join via a callback registration, phone dial-in, or by accessing an audio webcast. QIAGEN, based in the Netherlands, provides solutions enabling molecular insights from biological samples, supporting over 500,000 customers globally.

IGI Inex Holding has announced its strategic investment in quantumrock, a Munich-based AI and machine learning asset management company. This investment positions IGI with a relevant share based on quantumrock's valuation of €30 million, with options to increase its stake over time. The partnership aims to create innovative investment products that offer loss protection features desired by institutional investors. Quantumrock plans to leverage IGI’s precious stone holdings to develop unique investment strategies, enhancing their asset-backed investment product offerings.

QIAGEN N.V. (NYSE: QGEN) has expanded its NeuMoDx assay menu with new CE-IVD certified tests for Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6), bringing the total to 16 assays. These tests enhance monitoring for immunocompromised organ transplant patients, addressing significant postoperative risks. The company is also developing a multiplex assay for monkeypox and a new dual-target SARS-CoV-2 test, aimed at improving respiratory disease diagnostics. QIAGEN's automated solutions streamline workflows and improve lab efficiency.

QIAGEN has signed a collaboration agreement with Neuron23 to develop a companion diagnostic for a LRRK2 inhibitor aimed at treating Parkinson’s disease. This assay will utilize next-generation sequencing (NGS) technology to identify biomarkers predicting patient responsiveness. The collaboration enhances QIAGEN's NGS testing portfolio, expanding its precision medicine applications into neurology. Neuron23's LRRK2 inhibitor is in late-stage preclinical development, and this partnership is part of QIAGEN's strategy to leverage its expertise in molecular testing to support groundbreaking therapies.

Neuron23 and QIAGEN announced a collaboration on September 14, 2022, to develop the first companion diagnostic for Neuron23’s LRRK2 inhibitor aimed at treating Parkinson’s disease. Under the agreement, QIAGEN will create a clinical trial assay detecting biomarkers that predict patient responsiveness to the drug. This assay will be integrated into a next-generation sequencing workflow, facilitating concurrent submissions for FDA approval of both the diagnostic test and drug application.

The collaboration highlights the potential of precision medicine in neurodegenerative diseases.